Vascular Closure Devices Market

The market for Vascular Closure Devices was estimated at $1.9 billion in 2025; it is anticipated to increase to $2.7 billion by 2030, with projections indicating growth to around $3.9 billion by 2035.

Report ID:DS1801091

Author:Debadatta Patel - Senior Consultant

Published Date:January 2025

Datatree

Life Science

Medical Device

Vascular Closure Devices

Customization Available

Vascular Closure Devices - 2025-2035

Market Outlook
Market Key Insights
Growth Opportunity
Market Dynamics
Application
Recent Development
Impact Analysis

Report Summary

Market Data

Methodology

Table of Contents

Report Summary

Market Data

Methodology

Table of Contents

Global Vascular Closure Devices Market Outlook

Revenue, 2025

$1.9B

Forecast, 2035

$3.9B

CAGR, 2026 - 2035

7.6%

The Vascular Closure Devices (VCDs) industry revenue is expected to be around $1.9 billion in 2026 and expected to showcase growth with 7.6% CAGR between 2026 and 2035. With growth predicted in this field, the current vascular closure devices market is becoming increasingly important in vascular access. This growth is largely attributed to the rapid increase in procedures involving interventional cardiology and the increasing adoption of less invasive catheter based treatments. Cardiac cath labs and endovascular treatments are reliant on these devices to the extent that they are used in 71.4% of these operations. It is crucial in these facilities to have devices which provide fast and reliable haemostasis to ensure that patients are safe and treatment can be carried out efficiently. Centres doing outpatient and hospital catheterisations seek to get patients out of bed sooner in order to reduce complications arising after the procedure and to decrease the time patients have to stay in bed. This also helps in enhancing patient satisfaction. Because of their ability to be used on a wide variety of sheath sizes, as well as their predictable closure times and consistent performance, Active Vascular Closure Devices accounted for approximately $1.24 billion of the revenue in 2025.

Arterial closure devices are used for closing arterial sites which have been punctured after interventional procedures or other vascular procedures. These devices work through mechanical closure or by using bioabsorbable materials. Closure can be achieved through either method in a secure, consistent manner. The product offers benefits that include ease of deployment, compatibility with both the radial and the femoral approaches and the use of sutures or biocompatible plugs to close the wound, reducing time for the patient to be mobile again and to stop bleeding. Also included are standardised treatment regimens after procedures. Devices used in interventional cardiology, peripheral vascular treatments, structural heart interventions and neurovascular treatments require the device to seal the arterial puncture site to prevent bleeding. Day case surgical programmes are growing, as are the number of patients at high risk of further thrombotic episodes who are on anti coagulant medication. Also significant is innovation in the technique of actively closing any tear in the artery. This innovation improves the results of the procedure and makes the process simpler for staff involved.

Vascular Closure Devices market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035 — Vascular Closure Devices Market Outlook

Market Key Insights

The Vascular Closure Devices market is projected to grow from $1.9 billion in 2025 to $3.9 billion in 2035. This represents a CAGR of 7.6%, reflecting rising demand across Cardiovascular Procedures, Diagnostic Procedures, and Minimally Invasive Surgeries.
Leading manufacturers of in vitro diagnostics are Medtronic, Cardinal Health and Abbott Laboratories, key drivers of the markets competitive landscape.
The US and German markets are projected to see significant growth in the vascular closure devices market, expanding at a compound annual rate of 4.9 7.3% from 2025 to 2030.
These markets are expected to grow most, specifically Brazil, India and South Africa, at an annual compound rate between 8.7% and 10.5%.
Transition like Technological Advancements in VCDs is expected to add $218 million to the Vascular Closure Devices market growth by 2030.
Over the period 2025 to 2035, the market for vascular closure devices will increase by $2 billion. The firms developing vascular closure devices which are to be used in the treatment of the neurovascular and peripheral vascular system will achieve a greater market share.
The incidence of cardiovascular disease is rising. By the years 2025 to 2035, improvements in technology in the field of vascular closure devices is expected to bring about an expansion of 108% in the industry of vascular closure devices.

Vascular Closure Devices - Country Share Analysis

Opportunities in the Vascular Closure Devices

The Asia Pacific region is also experiencing a significant rise in demand for endovascular procedures which are performed to treat peripheral artery disease which affects an aging population. Closure devices are underutilised. In this region, there is an opportunity for a device which may be used for either radial or femoral access, especially in tertiary hospitals found in China, India and Southeast Asia. VCDs that reduce recovery times, fit the new reimbursement models and decrease complications are expected to drive the market at its fastest rate.

Growth Opportunities in North America and Asia-Pacific

Interventional cardiology applications in North America are where Vascular Closure Devices are strongest, a high volume of procedures such as percutaneous coronary interventions and complex endovascular interventions there leading demand for rapid arterial closure technologies and haemostasis technologies. Clinicians there are also treating peripheral blockages via less invasive methods, leading to increasing use of vascular closure devices in this region. Key region's of focus include the development of bioabsorbable closure systems for femoral access which are based on clinical evidence and are tailored for use in high acuity environments, bundles of products for radial and femoral access which are aligned to purchasing trends in hospitals, and the provision of solutions for ambulatory surgery centres which facilitate same day patient discharge. A high level of competition exists, with big global operations under strain from smaller niche businesses that offer simplified delivery systems, cost effective deployment and data intensive after sales monitoring. This supports new pricing models along with a network of healthcare providers who work together. This region has a high prevalence of conditions such as cardiovascular and peripheral vascular disease which mainly affect an ageing population. There is also high reimbursement for catheter based treatments. The region has a well developed infrastructure to support catheter based procedures. As a result, there is a preference for products that save time when closing wounds, reduce the workload of nurses, and reduce the risk of further complications at the point of insertion. This suggests a strategic case for developing vascular closure devices which offer clear advantages both to patients and to the healthcare system as a whole.

The demand in the region for vascular closure devices is primarily generated by interventional cardiology. However, the demand from the expanding numbers of neurovascular and peripheral vascular procedures in countries such as Japan, Australia and South Korea is assuming a more strategic importance. A diverse range of patient anatomy and varying operator skills in this region make versatile arterial closure devices necessary. Key region's of focus for growth include haemostasis technologies that can be scaled and cost reduced for large public hospitals which undertake a high number of procedures, regionalised bioabsorbable closure devices for medium sized hospitals and tailored training for facilities which perform cardiac and neurovascular treatments. What distinguishes competition in this industry is the interplay between global industry leaders and quickly growing Asian manufacturers. The latter take advantage of local manufacturing, adapt quickly to changing regulations, and their products are distributed through the region in order to capture a market share. This is especially prevalent in markets which are sensitive to price. Rising numbers of minimally invasive cardiology procedures are taking place alongside government funded improvements in hospital facilities, along with a general increase in the cost of healthcare. A trend has been noted among the medical profession of prioritising reducing the length of hospital stays following vascular interventions, in order to shorten waiting times for other patients. As a result, products which help to bring treatment to a close quickly are in high demand across the globe.

Market Dynamics and Supply Chain

Driver: Rising Cardiovascular Procedures and Demand for Faster Patient Recovery Times

A key driver for the vascular closure market is also the growing number of cardiovascular device and endovascular procedures globally. The prevalence of coronary artery disease, peripheral artery disease, and other vascular conditions is also increasing, leading to higher volumes of catheter-based interventions, including angioplasty and stent placement. Hospitals and intervention centers now routinely perform these minimally invasive procedures, boosting the adoption of closure devices.

Innovations in VCDs design, including bioabsorbable plugs, advanced suture systems, and extravascular sealants, are also significantly boosting market adoption. These devices reduce procedural complications, improve hemostasis, and enable precise deployment, even in complex vascular anatomies. The integration of real-time imaging guidance and user-friendly delivery systems enhances clinician confidence and patient outcomes. As hospitals and ambulatory centers prioritize safety and efficiency, these technological advancements are also accelerating the shift toward minimally invasive procedures, creating new growth opportunities for market leaders and supporting broader adoption worldwide.

Restraint: High costs and limited reimbursement hinder widespread adoption

The vascular closure market faces significant restraint from the high cost of advanced closure devices and inconsistent reimbursement policies, which limit adoption in price‑sensitive regions and smaller facilities. Premium systems often cost substantially more than traditional manual compression methods, discouraging procurement without clear reimbursement pathways. This results in slower adoption, especially in developing economies and budget‑constrained healthcare systems, reducing potential market revenue and skewing demand toward low‑cost alternatives.

Opportunity: US radial access cardiac interventions drive demand for advanced active Vascular Closure Devices and European ambulatory surgical centers favor cost-efficient passive Vascular Closure Devices for day-case endovascular procedures

US interventional cardiology programmes are rapidly increasing the use of radial access for percutaneous coronary interventions, thereby increasing the demand for vascular closure devices. Worldwide the VCDs market will be worth approximately $1,240,000,000 in the year 2025 and is estimated to reach $1,840,000,000 by 2030 at a predicted CAGR of 8.26%. Significant growth will be seen in active technologies that allow rapid control of bleeding, smaller sizes and the ability to work reliably in radial and femoral procedures, thereby enabling patients to move around sooner and facilitating faster lab work.

In Europe, the trend towards day case catheterisation and outpatient endovascular procedures is creating a cost sensitive niche for passive vascular closure devices in the ambulatory surgical sector. Projected growth in the global market for passive components is from $0.65 billion in 2025 to $0.88 billion in 2030, a compound annual growth rate of 6.3%.The key benefit to a practice involves smaller sheath sizes, streamlined nursing processes and rapid discharge pathways along with collagen based and plug based closure systems in high volume outpatient vascular centres.

Challenge: Competition from manual hemostasis and changing procedural preferences

A persistent challenge is the continued preference for manual compression and alternative closure techniques, especially in simple cases or where radial artery access reduces the need for closure devices. This limits the addressable procedural pool for femoral access VCDs and weakens demand growth. The prevalence of manual methods and evolving procedural trends constrain device penetration, compelling manufacturers to justify value over entrenched, low‑cost hemostasis approaches.

Supply Chain Landscape

Component Manufacturing

Medtronic PlcTeleflex Incorporated

Vascular Closure Devices

Abbott LaboratoriesCardiva Medical Inc

Medical Distribution

Cardinal HealthMedtronic Plc

Clinical End Users

HospitalsAmbulatory Surgical CentersCardiac Catheterization Labs

Component Manufacturing

Medtronic PlcTeleflex Incorporated

Vascular Closure Devices

Abbott LaboratoriesCardiva Medical Inc

Medical Distribution

Cardinal HealthMedtronic Plc

Clinical End Users

HospitalsAmbulatory Surgical CentersCardiac Catheterization Labs

Vascular Closure Devices - Supply Chain

Use Cases of Vascular Closure Devices in Cardiovascular Procedures & Diagnostic Procedures

Cardiovascular Procedures : In cardiovascular procedures, vascular closure devices are critical for achieving rapid hemostasis after catheter‑based interventions such as angioplasty and percutaneous coronary interventions. Hospitals and cardiac catheterization labs predominantly use suture‑mediated systems (e.g., Abbott’s Perclose ProGlide) alongside plug‑ and sealant‑based devices like Angio‑Seal (Terumo) and EXOSEAL (Cordis) to close femoral or radial access sites safely and efficiently, reducing bleeding and enabling early ambulation. Leading players Abbott, Terumo, Medtronic, Teleflex, and Cardinal Health are known for broad portfolios, strong clinical evidence, and global reach that support adoption in interventional cardiology and help improve patient outcomes.

Diagnostic Procedures : In diagnostic procedures, VCDs are essential for achieving rapid hemostasis following cardiac catheterization and angiography, helping patients recover quickly and reducing hospital stays. Devices such as Angio‑Seal, Perclose ProGlide, EXOSEAL, and MYNX are widely used by hospitals, interventional cardiology units and imaging centers, providing efficient arterial puncture closure after femoral or radial access. These systems enhance procedural efficiency, lessen complications, and improve patient comfort compared with manual compression. Leading market players Abbott, Terumo and Cardinal Health hold strong positions through diversified closure portfolios, global distribution and continuous innovation in hemostatic technology.

Minimally Invasive Surgeries : In minimally invasive surgeries, VCDs are critical for achieving rapid hemostasis after catheter‑based procedures such as angioplasty, stent placement, and endovascular interventions by sealing arterial puncture sites and reducing bleeding complications. Commonly used devices include suture‑based systems, collagen plug‑based closure tools, and extravascular sealant systems, primarily employed by hospitals and cardiovascular intervention centers to improve recovery time and patient comfort. Leading players like Abbott Laboratories, Terumo Corporation, Medtronic, Teleflex, and Cardinal Health hold strong market positions through extensive global distribution, robust clinical validation, and continuous innovation in device design and ease‑of‑use for enhanced outcomes.

Recent Developments

The vascular closure device market is witnessing rapid innovation with bioresorbable plugs, suture-mediated systems, and automated deployment technologies enhancing procedural efficiency and patient safety. Recent launches emphasize faster hemostasis, reduced complications, and compatibility with minimally invasive surgeries. Hospitals and interventional cardiology centers are adopting these devices to optimize catheterization procedures and outpatient interventions. A key trend is the growing preference for biocompatible materials and smart closure systems, driving adoption across cardiovascular and peripheral vascular applications while boosting clinician confidence and improving overall procedural outcomes.

June 2024 : In June 2024, Medtronic Plc announced a strategic partnership with Merit Medical Systems Inc. to advance vascular closure technologies and enhance clinical outcomes by combining Medtronic’s broad healthcare expertise with Merit’s innovative medical device capabilities. This collaboration aims to accelerate development of next‑generation closure solutions and strengthen product offerings globally.

May 2024 : In May 2024, Abbott Laboratories launched its next‑generation Perclose ProStyle vascular closure system in select European markets, focusing on improved management of complex large‑bore femoral access sites and procedural efficiency.

April 2023 : In April 2023, Abbott Laboratories completed the acquisition of Cardiovascular Systems, Inc., expanding its vascular technology portfolio with additional innovations to address complex arterial disease treatments and broaden its vascular closure and interventional solution offerings.

Impact of Industry Transitions on the Vascular Closure Devices Market

As a core segment of the Medical Device industry, the Vascular Closure Devices market develops in line with broader industry shifts. Over recent years, transitions such as Technological Advancements in VCDs and Integration of Advanced Biomaterials and Device Automation have redefined priorities across the Medical Device sector, influencing how the Vascular Closure Devices market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

Technological Advancements in VCDs

Advances in VCDs are changing the market dynamics by pushing the adoption of next generation vascular approximators, sealants that are passive and technologies that make use of collagen plugs in interventional cardiology and vascular surgeries of the periphery. In comparison with manual compression techniques, faster haemostasis, reduced access site complications and shorter patient recovery times for these systems indicate why VCDs are increasingly the method of choice in busy cath labs. With a growing emphasis on efficiency in the hospital environment and value based care, there is a growing requirement for the devices which provide operator independent secure closure. By 2030, the VCDs sector is expected to generate an additional USD196 million in revenue through these advancements. This innovation is key in the development of safer, more efficient procedures and in allowing manufacturers to charge a premium for their products. This is due to the devices enabling minimally invasive procedures.

Integration of Advanced Biomaterials and Device Automation

Recent industry developments highlight a shift toward advanced biomaterials and automated vascular closure systems, improving patient outcomes and procedural precision. Innovations such as bioresorbable polymers, hemostatic patches, and absorbable collagen plugs enhance arterial sealing while minimizing infection risk and tissue trauma. Automation features in closure devices reduce manual handling errors, streamline workflows, and shorten procedure time, benefiting interventional cardiology and peripheral vascular intervention sectors. This evolution also impacts medical device manufacturing and regenerative medicine, encouraging collaborations between material scientists, software developers, and clinical specialists to design next-generation closure systems that combine safety, efficiency, and reproducibility.